International Journal of Clinical Research
International Journal of Clinical Research. 2025; 9: (5) ; 10.12208/j.ijcr.20250245 .
总浏览量: 99
青海红十字医院 青海西宁
*通讯作者: 孟令东,单位:青海红十字医院 青海西宁;
目的 探讨左西孟旦在老年肺动脉高压患者治疗中的应用意义。方法 回顾性分析2021年1月至2025年1月期间本院收治的100例肺动脉高压老年患者资料,根据患者治疗方案不同分为对照组(n=50)与研究组(n=50)。对照组给予常规对症治疗,研究组加用左西孟旦,收集两组治疗数据,分析不同治疗策略的效果。结果 治疗前,两组患者各指标比较并无明显差异(P>0.05);治疗后,与对照组相比,研究组下肢周径、肺动脉压更小,而24h尿量、PaO2水平更高(P<0.05);治疗后,与对照组相比,研究组6min步行距离更长,而MLHFQ 评分更低(P<0.05);两组患者不良反应发生率对比并无明显差异(P>0.05)。结论 老年肺动脉高压患者应用左西孟旦治疗可获得满意效果,有助于降低患者肺动脉压,提高生活质量,且安全可靠,值得临床推广应用。
Objective To explore the application significance of levosimendan in the treatment of elderly patients with pulmonary hypertension. Methods A retrospective analysis was conducted on the data of 100 elderly patients with pulmonary arterial hypertension admitted to our hospital from January 2021 to January 2025. The patients were divided into a control group (n=50) and a study group (n=50) according to different treatment plans. The control group received routine symptomatic treatment, while the study group received additional treatment with levosimendan. Data from both treatment groups were collected to analyze the effectiveness of different treatment strategies. Results Before treatment, there was no significant difference in various indicators between the two groups of patients (P>0.05); After treatment, compared with the control group, the lower limb circumference and pulmonary artery pressure were smaller in the study group, while 24-hour urine output and PaO2 levels were higher (P<0.05); After treatment, compared with the control group, the study group had a longer 6-minute walking distance and a lower MLHFQ score (P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups of patients (P>0.05). Conclusion The use of levosimendan in the treatment of elderly patients with pulmonary arterial hypertension can achieve satisfactory results, help reduce pulmonary artery pressure, improve quality of life, and is safe and reliable. It is worthy of clinical promotion and application.
[1] 林叶涛,刘超远. 左西孟旦辅助常规西药治疗重症肺动脉高压并右心衰竭患者的疗效及安全性分析[J]. 中国实用医药,2024,19(6):96-99.
[2] 张晓丹,谢玉良,高梦丹,等. 基于网络药理学方法与分子对接技术探究左西孟旦治疗低氧肺动脉高压的作用机制[J]. 中国药理学通报,2024,40(3):565-573.
[3] 晏露,赵智慧,赵青,等. 左西孟旦治疗重症肺动脉高压合并右心衰竭患者的有效性和安全性观察[J]. 中国循环杂志,2022,37(3):239-242.
[4] 刘明涛,闫鹏鹏. 左西孟旦治疗肺动脉高压老年患者的疗效与安全性研究[J]. 中国现代医生,2022,60(19):64-67.
[5] 韦斌,张朝勇,邓燕,等. 间断重复应用左西孟旦治疗肺动脉高压右心衰竭的临床观察[J]. 中国药房,2022,33(14): 1754-1758.
[6] 王林艳. 左西孟旦与西地那非联合用药方案治疗慢性心力衰竭并发肺动脉高压的临床分析[J]. 中国现代药物应用, 2021,15(7):133-135.
[7] 邢印龙. 左西孟旦与西地那非联合用药方案治疗慢性心力衰竭并发肺动脉高压的临床研究[J]. 吉林医学,2020, 41(12):2953-2955.
[8] 季尚明. 左西孟旦联合曲美他嗪治疗肺动脉高压的疗效观察[J]. 实用中西医结合临床,2020,20(2):137-138.
[9] 罗勤,金旗,柳志红,等. 左西孟旦治疗重症肺动脉高压合并右心衰竭患者的临床观察[J]. 中国呼吸与危重监护杂志,2021,20(3):203-205.